These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23978034)

  • 1. [Sorafenib monotherapy for FLT3-ITD positive acute myeloid leukemia: a case report].
    Jiang ZH; Feng FE; Lin XQ; Lu J
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):736. PubMed ID: 23978034
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia.
    Mohan BP; How GF; Loh Y; Linn YC
    Br J Haematol; 2012 Apr; 157(1):131-2. PubMed ID: 22050655
    [No Abstract]   [Full Text] [Related]  

  • 3. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
    Gill H; Man CH; Ip AH; Choi WW; Chow HC; Kwong YL; Leung AY
    Haematologica; 2015 Jul; 100(7):e250-3. PubMed ID: 25820334
    [No Abstract]   [Full Text] [Related]  

  • 4. Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.
    Giri S; Hamdeh S; Bhatt VR; Schwarz JK
    J Natl Compr Canc Netw; 2015 May; 13(5):508-14. PubMed ID: 25964636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect.
    Liegel J; Courville E; Sachs Z; Ustun C
    Haematologica; 2014 Nov; 99(11):e222-4. PubMed ID: 25015937
    [No Abstract]   [Full Text] [Related]  

  • 6. Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
    Antar A; Kharfan-Dabaja MA; Mahfouz R; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):298-302. PubMed ID: 25550214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia.
    Fontanelli G; Rocco M; Caracciolo F; Benedetti E; Buda G; Orciuolo E; Carulli G; Galimberti S; Azzarà A; Petrini M
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):e13-7. PubMed ID: 24144836
    [No Abstract]   [Full Text] [Related]  

  • 8. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
    Baker SD; Zimmerman EI; Wang YD; Orwick S; Zatechka DS; Buaboonnam J; Neale GA; Olsen SR; Enemark EJ; Shurtleff S; Rubnitz JE; Mullighan CG; Inaba H
    Clin Cancer Res; 2013 Oct; 19(20):5758-68. PubMed ID: 23969938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation.
    Tschan-Plessl A; Halter JP; Heim D; Medinger M; Passweg JR; Gerull S
    Ann Hematol; 2015 Nov; 94(11):1899-905. PubMed ID: 26233683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
    De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F
    Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.
    Metzelder SK; Schroeder T; Lübbert M; Ditschkowski M; Götze K; Scholl S; Meyer RG; Dreger P; Basara N; Fey MF; Salih HR; Finck A; Pabst T; Giagounidis A; Kobbe G; Wollmer E; Finke J; Neubauer A; Burchert A
    Eur J Cancer; 2017 Nov; 86():233-239. PubMed ID: 29055209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience.
    Urbino I; Secreto C; Apolito V; Olivi M; Arrigo G; Boscaro E; Catania FM; D'Ardia S; Frairia C; Giai V; Freilone R; Bruno B; Lanzarone G; Giaccone L; Busca A; Dellacasa CM; Ferrero D; Audisio E; Cerrano M
    Leuk Res; 2024 Jan; 136():107421. PubMed ID: 38042648
    [No Abstract]   [Full Text] [Related]  

  • 13. Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
    Fathi AT; Lin WM; Durazzo T; Piris A; Sadrzadeh H; Bernardo L; Borger DR; McAfee SL; Kroshinsky D; Chen YB
    J Clin Oncol; 2016 Mar; 34(8):e70-2. PubMed ID: 25024084
    [No Abstract]   [Full Text] [Related]  

  • 14. Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
    Tarlock K; Chang B; Cooper T; Gross T; Gupta S; Neudorf S; Adlard K; Ho PA; McGoldrick S; Watt T; Templeman T; Sisler I; Garee A; Thomson B; Woolfrey A; Estey E; Meshinchi S; Pollard JA
    Pediatr Blood Cancer; 2015 Jun; 62(6):1048-54. PubMed ID: 25662999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.
    Guenounou S; Delabesse E; Récher C
    Eur J Haematol; 2014 Dec; 93(6):533-6. PubMed ID: 24689895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
    Battipaglia G; Ruggeri A; Massoud R; El Cheikh J; Jestin M; Antar A; Ahmed SO; Rasheed W; Shaheen M; Belhocine R; Brissot E; Dulery R; Eder S; Giannotti F; Isnard F; Lapusan S; Rubio MT; Vekhoff A; Aljurf M; Legrand O; Mohty M; Bazarbachi A
    Cancer; 2017 Aug; 123(15):2867-2874. PubMed ID: 28387928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib Therapy for Pediatric Acute Myeloid Leukemia with FMS-like Tyrosine Kinase 3-internal Tandem Duplication Mutations: 2 Case Reports.
    Osone S; Imamura T; Kanayama T; Tsuma Y; Kawashima-Goto S; Nakatani T; Sugimoto A; Takai A; Miyachi M; Tamura S; Ishida H; Hosoi H
    J Pediatr Hematol Oncol; 2017 May; 39(4):e199-e202. PubMed ID: 27571118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib-induced Posterior Reversible Encephalopathy Syndrome in a Child With FLT3-ITD-positive Acute Myeloid Leukemia.
    Tavil B; Isgandarova F; Bayhan T; Unal S; Kuskonmaz B; Gumruk F; Cetin M
    J Pediatr Hematol Oncol; 2016 Apr; 38(3):240-2. PubMed ID: 26907662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Zu YL; Zhang YL; Zhou J; Han LJ; Zhao HF; Gui RR; Hou YJ; Song YP
    Zhonghua Nei Ke Za Zhi; 2016 Aug; 55(8):634-6. PubMed ID: 27480560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia.
    Cummins KD; Jane SM; Ninkovic S; Bazargan A; Filshie R; Sutrave G; Hertzberg M; Scott A; Lane S; Yannakou CK; Ritchie D; D'Rozario J; Black J; Bavishi K; Wei A
    Blood Cancer J; 2014 Aug; 4(8):e237. PubMed ID: 25105536
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.